Patents Examined by Jean P Cornet
  • Patent number: 11951113
    Abstract: A combination composition including as active components, in synergistically effective amounts of (i) a steroidal saponin of natural or synthetic origin, a pharmaceutical acceptable salt thereof or a plant extract containing steroidal saponin, and (ii) at least a first polyphenolic compound selected from the group of hydroxycinnamic acids, flavonoids, hydroxybenzoic acids, and (iii) optionally, a second polyphenolic compound, wherein the second polyphenolic compound is hydroxycinnamic acids and its use in preventing, inhibiting, retarding or treating a subject suffering from a neurodegenerative disease or condition.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: April 9, 2024
    Assignee: NEURALIA
    Inventor: Noëlle Callizot
  • Patent number: 11944635
    Abstract: Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.
    Type: Grant
    Filed: July 24, 2023
    Date of Patent: April 2, 2024
    Assignee: POVIVA CORP
    Inventors: John Docherty, Christopher Andrew Bunka
  • Patent number: 11944611
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: April 2, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant, Dana J. Levine
  • Patent number: 11944612
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: April 2, 2024
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
  • Patent number: 11931355
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: March 19, 2024
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Magali B. Hickey, Jennifer Vandiver
  • Patent number: 11918548
    Abstract: The invention relates to vascular disrupting agent (VDA) such as combretastatins for treating avascular or hypovascular micro-tumors with a diameter below 20 mm.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: March 5, 2024
    Assignee: Katholieke Universiteit Leuven
    Inventor: Yicheng Ni
  • Patent number: 11918565
    Abstract: Provided herein are methods of administering to a peroneal and a tibial nerve of a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of a patient; (b) inserting the injection needle into the patient at the entry point; (c) administering to a sciatic nerve of the patient via the injection needle saline and a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome.
    Type: Grant
    Filed: February 2, 2023
    Date of Patent: March 5, 2024
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Roy Winston, Mary DiGiorgi
  • Patent number: 11911505
    Abstract: The present invention relates to a liquid pharmaceutical formulation of hypoglycaemic sulfonamide, intended for oral or ophthalmic administration. The present invention relates in particular to an oral formulation particularly suitable for paediatric use.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: February 27, 2024
    Assignee: AMMTEK
    Inventor: Marianne Berdugo Polak
  • Patent number: 11912690
    Abstract: The present invention relates to a pidolate salt and malate salt of a compound represented by a formula 1 with an excellent liquid-phase stability, solid-phase stability, water solubility, precipitation stability and hygroscopicity all together as a compound for preventing and treating diseases mediated by an acid pump antagonistic activity, as well as a method for preparing the same.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: February 27, 2024
    Assignee: HK INNO.N CORPORATION
    Inventors: Eun Sun Kim, Min Kyoung Lee, Sung Ah Lee, Kwang Do Choi, Jae Sun Kim, Hyung Chul Yoo
  • Patent number: 11905282
    Abstract: A 1-cyclopropyl-7-(4-((5-(2,4-dichlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
    Type: Grant
    Filed: September 25, 2023
    Date of Patent: February 20, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11896567
    Abstract: An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 125 mg to approximately 175 mg ibuprofen in combination with approximately 475 mg to approximately 525 mg paracetamol; or b) approximately 275 mg to approximately 325 mg ibuprofen in combination with approximately 975 mg to approximately 1,025 mg paracetamol.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: February 13, 2024
    Assignee: AFT Pharmaceuticals Limited
    Inventor: Hartley C. Atkinson
  • Patent number: 11884654
    Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Trevor T. Charvat, Junfa Fan, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jeffrey P. McMahon, Jay Powers, Sreenivas Punna, Ju Yang
  • Patent number: 11878956
    Abstract: The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: January 23, 2024
    Assignee: Inspirna, Inc.
    Inventors: Stephen Wald, Eduardo J. Martinez, Samuel Stratford, Amanda Buist, Joseph Benson, Jonathan Loughrey
  • Patent number: 11850245
    Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: December 26, 2023
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Michael T. Nordsiek, Jefferson J. Gregory
  • Patent number: 11844776
    Abstract: The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve disorder comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): R4O—R5m??(IIa) wherein R4 is lower alkyl, R5 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: December 19, 2023
    Assignees: OSAKA CITY UNIVERSITY, SENJU PHARMACEUTICAL CO., LTD.
    Inventor: Shinji Hirotsune
  • Patent number: 11844798
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: December 19, 2023
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins University
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
  • Patent number: 11834413
    Abstract: The present disclosure relates to compounds which exhibit activity in the inhibition of platelet aggregation as well as pharmaceutical compositions comprising these compounds and methods of treatment of vascular diseases by administration of these compounds or the pharmaceutical compositions.
    Type: Grant
    Filed: May 25, 2023
    Date of Patent: December 5, 2023
    Assignee: SHANGHAI CUREGENE PHARMACEUTICAL CO LTD.
    Inventors: Zi-Qiang Gu, Yuanchao Zhang, Gongxin He, Kai Hou, Hao Wu
  • Patent number: 11833238
    Abstract: The present invention relates to the composition and method of use for the topical application of the potent androgen hormone dihydrotestosterone (DHT), used alone or in fixed combination with other hair growth medications; including other androgens, bimatoprost, other prostamides, prostaglandins, minoxidil or apocrine hair growth factors to promote and enhance hair growth of terminal mustache hair, beard hair, also chest hair, and other male androgen sensitive or dependent hair growth in humans or animals.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: December 5, 2023
    Inventor: Edward Dunne Corboy, Jr.
  • Patent number: 11826373
    Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: November 28, 2023
    Assignee: Galera Labs, LLC
    Inventors: Jeffery L. Keene, Dennis P. Riley, Robert A. Beardsley
  • Patent number: 11826466
    Abstract: A ready to use or ready to dilute for use, stable liquid Bendamustine solution formed of 90 to about 200 mg/mL Bendamustine Hydrochloride or a hydrate form thereof, and a co-solvent consisting of 1% v/v to 12% v/v water and 88% v/v to 99% v/v N,N-Dimethylacetamide (DMA). The liquid Bendamustine solution is room-temperature stable for at least 90 days. Optionally, 0.01 to about 0.5 mg/mL antioxidant, preferably, butylated hydroxytoluene is included in the solution.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: November 28, 2023
    Assignee: Navinta, LLC
    Inventor: Mahendra R. Patel